Canopy Animal Health Pet CBD Products Awarded NASC Quality Seal
NASC Quality Seal recognizes manufacturers who comply with the highest quality standards for their rigorous research and development efforts in the creation of science-backed CBD products for pets
ATLANTA (January 20, 2021) — Canopy Animal Health – a world-leading diversified cannabis and cannabinoid-based consumer product company, Canopy Growth Corporation (TSX: WEED, NASDAQ: CGC) – has been granted the right to display the Quality Seal from the National Animal Supplement Council (NASC) for their CBD products for dogs, which are expected to be launched in the coming weeks. The NASC is a non-profit group dedicated to protecting and enhancing the health of companion animals throughout the United States. To earn the NASC approval, Canopy Animal Health passed rigorous standards in proving the quality and safety of its products. “Canopy Animal Health has conducted a great deal of critical research over the last four years in the development of science-based CBD products that improve the lives of pets,” said Robert Menardi, Director of Veterinary Educational and Technical Services at Canopy Animal Health. “The NASC Quality Seal affirms our dedication to providing safe and high-quality CBD products for companion animals.” The NASC created the Quality Seal Program to help standardize and elevate the animal health industry. To retain permission to display the seal on its products, Canopy Animal Health must pass an independent facility audit every two years, and demonstrate continued compliance to strict standards and regulations, including:
● Stringent labeling guidelines, such as specific warnings and caution statements for particular ingredients recommended by the FDA’s Center for Veterinary Medicine
● Random product testing by an independent lab to ensure ingredients meet label claims
● Documented quality control and production procedures ensuring a consistent and quality product
● Ingredients reviewed by the NASC Scientific Advisory Committee
● Real-time product monitoring and mandatory adverse event reporting
“Congratulations to Canopy Animal Health for completing the NASC Quality Audit. We’re proud of our partnership with Canopy Animal Health and their dedication to quality, as demonstrated during our audit process,” said Bill Bookout, President, National Animal Supplement Council. “Canopy Animal Health has established themselves a leader in the pet CBD space through their commitment to providing quality scientific research, and we applaud their focus and work in the animal health industry. ” Canopy Animal Health is leading the industry in pet CBD research, with more than 32 studies exploring the safety of cannabinoids in animal health. The Canopy Animal Health leadership team also includes multiple veterinarians and boasts unparalleled animal industry expertise, including playing key roles in the development of the most recognizable animal health brands. The company will soon market CBD animal health products leveraging their rigorous research and development efforts, state-of-the-art manufacturing and extensive product testing for purity and safety.
For more information on NASC and the Quality Seal, please visit: https://nasc.cc/
About Canopy Animal Health
Canopy Animal Health is a wholly owned subsidiary of Canopy Growth (TSX: WEED, NASDAQ:CGC), committed to improving the lives of companion animals through tested and scientifically proven cannabinoid and CBD products. With the industry’s largest financial outlay for research and development, Canopy Animal Health is working to develop products that solve real-world pet issues as defined by practicing veterinarians. For more information, please visit canopyanimalhealth.com.
About Canopy Growth Corporation
Canopy Growth (TSX:WEED, NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States, and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com.
For more information, contact:
Media Relations Representative
Vice President, Investor Relations and Competitive Intelligence
Director, Investor Relations